Association Between Papillary Thyroid Carcinoma and Vertebral Fracture

Area of Science:

• Endocrinology
• Oncology
• Bone Metabolism

Background:

• Thyroid-stimulating hormone (TSH) suppression with levothyroxine is a known fracture risk factor.
• The risk of vertebral fracture (VF) in papillary thyroid carcinoma (PTC) patients prior to TSH suppression remains unclear.

Purpose of the Study:

• To investigate if PTC patients exhibit a higher risk of VF compared to healthy individuals.
• To determine the association between PTC and VF before TSH suppression.

Main Methods:

• A matched case-control study comparing 43 postoperative PTC patients and 43 healthy controls.
• Evaluation of serum/urinary parameters, bone mineral density (BMD), and VF presence.
• Statistical analysis using chi-squared, Mann-Whitney U-test, and logistic regression.

Main Results:

• PTC patients had higher BMI, HbA1c, phosphorus, and lower intact parathyroid hormone (PTH).
• No significant difference in lumbar or femoral neck BMD between groups.
• VF prevalence was significantly higher in PTC patients (44.1%) versus controls (16.3%).
• PTC was independently associated with VF risk (OR, 5.63; 95% CI: 1.82–17.5) after adjusting for confounders.

Conclusions:

• An association exists between PTC and an increased risk of VF, independent of sex, BMI, glucose metabolism, and BMD.
• This highlights the importance of assessing fracture risk in PTC patients before initiating TSH suppression therapy.